CO6801648A2 - Formulación para anticuerpo anti-α4β7 - Google Patents
Formulación para anticuerpo anti-α4β7Info
- Publication number
- CO6801648A2 CO6801648A2 CO13259852A CO13259852A CO6801648A2 CO 6801648 A2 CO6801648 A2 CO 6801648A2 CO 13259852 A CO13259852 A CO 13259852A CO 13259852 A CO13259852 A CO 13259852A CO 6801648 A2 CO6801648 A2 CO 6801648A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481522P | 2011-05-02 | 2011-05-02 | |
| US201161544054P | 2011-10-06 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6801648A2 true CO6801648A2 (es) | 2013-11-29 |
Family
ID=46147702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13259852A CO6801648A2 (es) | 2011-05-02 | 2013-11-01 | Formulación para anticuerpo anti-α4β7 |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US10040855B2 (es) |
| EP (5) | EP4378959A3 (es) |
| JP (5) | JP6190359B2 (es) |
| KR (7) | KR101884406B1 (es) |
| CN (4) | CN107998388B (es) |
| AR (1) | AR086238A1 (es) |
| AU (5) | AU2012250872B2 (es) |
| CA (2) | CA2834900C (es) |
| CL (3) | CL2013003145A1 (es) |
| CO (1) | CO6801648A2 (es) |
| CR (1) | CR20130556A (es) |
| CY (1) | CY1119436T1 (es) |
| DK (1) | DK2704742T3 (es) |
| DO (1) | DOP2013000252A (es) |
| EA (1) | EA032625B1 (es) |
| EC (1) | ECSP22046340A (es) |
| ES (1) | ES2646717T3 (es) |
| GE (1) | GEP20186866B (es) |
| HK (1) | HK1253911A1 (es) |
| HR (1) | HRP20171457T1 (es) |
| HU (1) | HUE036664T2 (es) |
| IL (6) | IL305583A (es) |
| LT (1) | LT2704742T (es) |
| ME (1) | ME02858B (es) |
| MX (4) | MX354101B (es) |
| MY (1) | MY188820A (es) |
| PE (1) | PE20141672A1 (es) |
| PH (2) | PH12018502221A1 (es) |
| PL (1) | PL2704742T3 (es) |
| PT (1) | PT2704742T (es) |
| RS (1) | RS56429B1 (es) |
| SG (1) | SG194730A1 (es) |
| SI (1) | SI2704742T1 (es) |
| TW (5) | TWI698254B (es) |
| UY (1) | UY34054A (es) |
| WO (1) | WO2012151247A2 (es) |
| ZA (2) | ZA201308168B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2521568T3 (en) | 2010-01-06 | 2018-11-19 | Dyax Corp | PLASMACALLIC CLEANING PROTEINS |
| MX344294B (es) * | 2010-10-06 | 2016-12-13 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| WO2012101253A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| EP4378959A3 (en) * | 2011-05-02 | 2024-09-04 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| KR20140047628A (ko) | 2011-07-06 | 2014-04-22 | 네스텍 소시에테아노님 | Ｔｎｆ알파로의 생물학적 치료요법에 대한 중화 자가항체의 검출을 위한 검정 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9764093B2 (en) * | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
| EP2970502A4 (en) | 2013-03-15 | 2016-11-30 | Dyax Corp | ANTI-PLASMA KALLIKREIN ANTIBODY |
| EA034376B1 (ru) * | 2013-07-05 | 2020-01-31 | Интегра Медикал Инк. | Композиции для оздоровления полости рта |
| KR101712245B1 (ko) * | 2013-11-29 | 2017-03-06 | 아레스 트레이딩 에스.에이. | TNFR 및 면역글로블린 Fc 영역을 포함하는 융합 단백질을 포함하는 액상 제제 |
| WO2015148790A1 (en) | 2014-03-27 | 2015-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| EP3204424B1 (en) | 2014-10-06 | 2023-11-29 | ChemoCentryx, Inc. | Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease |
| US20170327584A1 (en) | 2014-11-26 | 2017-11-16 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the Treatment of Fistulizing Crohn's Disease |
| EP3226895B1 (en) * | 2014-12-03 | 2020-07-22 | CSL Behring AG | Pharmaceutical product with increased stability comprising immunoglobulins |
| CA2969609C (en) * | 2014-12-05 | 2023-02-28 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| EA201792161A1 (ru) * | 2015-03-30 | 2018-04-30 | Дайэкс Корп. | Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека |
| MA42657A (fr) | 2015-08-18 | 2018-06-27 | Regeneron Pharma | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines |
| WO2017100679A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| EP3397287A1 (en) * | 2015-12-30 | 2018-11-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
| USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
| WO2017160699A2 (en) * | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| KR102667332B1 (ko) | 2016-03-14 | 2024-05-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 이식편대숙주 질환을 치료하거나 예방하는 방법 |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| US10918716B2 (en) | 2016-05-04 | 2021-02-16 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating Crohn's disease |
| EP3468597A1 (en) * | 2016-06-12 | 2019-04-17 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| CN110337445B (zh) * | 2016-12-23 | 2023-05-23 | 印度血清研究所私人有限公司 | 用于提高哺乳动物细胞培养物中的抗体生产力并最小化下游、配制过程中的聚集的改进的方法，以及由其获得的稳定抗体制剂 |
| CN108686204A (zh) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
| AU2018256840A1 (en) | 2017-04-28 | 2019-11-07 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab) |
| BR112020003632A2 (pt) * | 2017-08-25 | 2020-10-27 | Omeros Corporation | método de tratamento de um indivíduo que sofre ou corre risco de desenvolver ahus |
| BR112020020741A2 (pt) * | 2018-04-10 | 2021-01-19 | Dr. Reddy's Laboratories Limited | Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. |
| CN112218654A (zh) * | 2018-04-10 | 2021-01-12 | 雷迪博士实验室有限公司 | 抗体制剂 |
| EP3773696A4 (en) * | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Stable formulations of therapeutic antibody |
| US20210187107A1 (en) * | 2018-08-29 | 2021-06-24 | Glaxosmithkline Intellectual Property Development Limited | Methods of preparing stable liquid therapeutic protein compositions |
| CA3124701A1 (en) * | 2019-01-08 | 2020-07-16 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| UA128098C2 (uk) | 2019-02-18 | 2024-04-03 | Елі Ліллі Енд Компані | Водна фармацевтична композиція антитіла проти il-17a |
| MX2021015302A (es) * | 2019-06-10 | 2022-01-18 | Takeda Pharmaceuticals Co | Metodos de purificacion de anticuerpos y composiciones de estos. |
| AU2020364436A1 (en) * | 2019-10-11 | 2022-04-21 | Dr. Reddy's Laboratories Limited | Stable formulation of integrin antibody |
| TW202222832A (zh) * | 2020-07-31 | 2022-06-16 | 美商建南德克公司 | 抗整聯蛋白β７抗體調配物及裝置 |
| EP4243859A4 (en) * | 2020-11-12 | 2024-10-16 | Dr Reddys Laboratories Ltd | STABLE AQUEOUS HIGHLY CONCENTRATED FORMULATION OF AN INTEGRIN ANTIBODY |
| EP4259192A1 (en) * | 2020-12-09 | 2023-10-18 | Dr. Reddy's Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
| US20240254237A1 (en) * | 2021-06-04 | 2024-08-01 | Polpharma Biologics S.A. | Vedolizumab formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| WO2023126411A1 (en) | 2021-12-27 | 2023-07-06 | Polpharma Biologics S.A. | Vedolizumab formulation |
| WO2023230620A1 (en) * | 2022-05-27 | 2023-11-30 | Sonnet BioTherapeutics, Inc. | Il-12-albumin-binding domain fusion protein formulations and methods of use thereof |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
| US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
| EP0303463B1 (en) | 1987-08-11 | 1994-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Method to control leukocyte extravasation |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| WO1990007321A2 (en) | 1988-12-23 | 1990-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte receptor homing sequences and their uses |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| IL95501A (en) | 1989-09-01 | 1997-04-15 | Hutchinson Fred Cancer Res | Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0531472B1 (en) | 1991-03-06 | 2003-08-13 | MERCK PATENT GmbH | Humanized monoclonal antibodies |
| US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| EP0625912B1 (en) | 1992-02-12 | 1997-04-16 | Biogen, Inc. | Treatment for inflammatory bowel disease |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| AU4390893A (en) | 1992-05-21 | 1993-12-13 | Center For Blood Research, Inc., The | A novel receptor for alpha4 integrins and methods based thereon |
| WO1994012214A1 (en) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
| WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| ATE182625T1 (de) | 1993-01-12 | 1999-08-15 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| WO1994017828A2 (en) | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
| US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
| JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| KR100367948B1 (ko) | 1994-01-25 | 2003-07-12 | 엘란 파마슈티칼스, 인크. | 백혈구부착분자vla-4에대한인체화된항체 |
| US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
| US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
| GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| EP0808367B1 (en) | 1995-02-10 | 2007-07-11 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins and uses thereof |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| PL215263B1 (pl) | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| CA2485681C (en) | 2002-05-24 | 2012-10-16 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| WO2004046092A2 (en) | 2002-11-18 | 2004-06-03 | Chemocentryx | Aryl sulfonamides |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| WO2004075913A1 (ja) | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
| HUE030579T2 (en) | 2003-04-04 | 2017-05-29 | Genentech Inc | High Concentration Antibody And Protein Products |
| PL2322556T3 (pl) | 2004-09-03 | 2016-04-29 | Genentech Inc | Humanizowani antagoniści anty-beta7 i ich zastosowania |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| CA2600608A1 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising human igg2 antibody and chelating agent |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| EP1948691A1 (en) * | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
| WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| MX2008013508A (es) | 2006-04-21 | 2008-10-31 | Novartis Ag | Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40. |
| EP2109480B1 (en) | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| US9111016B2 (en) | 2007-07-06 | 2015-08-18 | Stereotaxis, Inc. | Management of live remote medical display |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| BRPI0819932A2 (pt) * | 2007-12-13 | 2019-07-30 | Glaxo Group Ltd | composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| CN103720587A (zh) * | 2008-02-07 | 2014-04-16 | 安姆根有限公司 | 稳定化的蛋白组合物 |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| SG174344A1 (en) | 2009-03-20 | 2011-11-28 | Amgen Inc | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| CN101533504A (zh) * | 2009-04-27 | 2009-09-16 | 刘文祥 | 电子医务系统及其装置 |
| CN107693791B (zh) | 2010-02-26 | 2022-06-07 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| EP4378959A3 (en) | 2011-05-02 | 2024-09-04 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
-
2012
- 2012-05-02 EP EP24167547.9A patent/EP4378959A3/en active Pending
- 2012-05-02 SG SG2013080940A patent/SG194730A1/en unknown
- 2012-05-02 ME MEP-2017-227A patent/ME02858B/me unknown
- 2012-05-02 DK DK12722973.0T patent/DK2704742T3/en active
- 2012-05-02 MY MYPI2013003974A patent/MY188820A/en unknown
- 2012-05-02 AR ARP120101540A patent/AR086238A1/es not_active Application Discontinuation
- 2012-05-02 LT LTEP12722973.0T patent/LT2704742T/lt unknown
- 2012-05-02 TW TW106123969A patent/TWI698254B/zh active
- 2012-05-02 PE PE2013002433A patent/PE20141672A1/es active IP Right Grant
- 2012-05-02 SI SI201231076T patent/SI2704742T1/sl unknown
- 2012-05-02 UY UY0001034054A patent/UY34054A/es not_active Application Discontinuation
- 2012-05-02 CA CA2834900A patent/CA2834900C/en active Active
- 2012-05-02 JP JP2014509377A patent/JP6190359B2/ja active Active
- 2012-05-02 CN CN201711133991.0A patent/CN107998388B/zh active Active
- 2012-05-02 WO PCT/US2012/036069 patent/WO2012151247A2/en active Application Filing
- 2012-05-02 CA CA3051418A patent/CA3051418C/en active Active
- 2012-05-02 KR KR1020177012979A patent/KR101884406B1/ko active IP Right Grant
- 2012-05-02 EP EP17180247.3A patent/EP3311834A1/en active Pending
- 2012-05-02 EP EP24167554.5A patent/EP4403579A3/en active Pending
- 2012-05-02 MX MX2013012725A patent/MX354101B/es active IP Right Grant
- 2012-05-02 EP EP12722973.0A patent/EP2704742B1/en not_active Revoked
- 2012-05-02 KR KR1020237002891A patent/KR20230021758A/ko not_active Application Discontinuation
- 2012-05-02 TW TW109140548A patent/TWI799757B/zh active
- 2012-05-02 EA EA201391613A patent/EA032625B1/ru not_active IP Right Cessation
- 2012-05-02 ES ES12722973.0T patent/ES2646717T3/es active Active
- 2012-05-02 KR KR1020207020503A patent/KR102308938B1/ko active IP Right Grant
- 2012-05-02 MX MX2017007134A patent/MX367097B/es unknown
- 2012-05-02 PL PL12722973T patent/PL2704742T3/pl unknown
- 2012-05-02 AU AU2012250872A patent/AU2012250872B2/en active Active
- 2012-05-02 CN CN201810453958.4A patent/CN108969469A/zh active Pending
- 2012-05-02 TW TW108104506A patent/TWI723339B/zh active
- 2012-05-02 IL IL305583A patent/IL305583A/en unknown
- 2012-05-02 RS RS20171015A patent/RS56429B1/sr unknown
- 2012-05-02 TW TW111148303A patent/TWI832619B/zh active
- 2012-05-02 EP EP24167555.2A patent/EP4438625A2/en active Pending
- 2012-05-02 CN CN201280021789.8A patent/CN103533959B/zh active Active
- 2012-05-02 KR KR1020137031205A patent/KR101875155B1/ko active IP Right Grant
- 2012-05-02 TW TW101115710A patent/TWI638661B/zh active
- 2012-05-02 HU HUE12722973A patent/HUE036664T2/hu unknown
- 2012-05-02 KR KR1020187018702A patent/KR102014512B1/ko active IP Right Grant
- 2012-05-02 KR KR1020197024347A patent/KR102136208B1/ko active IP Right Grant
- 2012-05-02 CN CN201810453956.5A patent/CN108969761A/zh active Pending
- 2012-05-02 KR KR1020217031194A patent/KR102493433B1/ko active IP Right Review Request
- 2012-05-02 PT PT127229730T patent/PT2704742T/pt unknown
- 2012-05-02 GE GEAP201213302A patent/GEP20186866B/en unknown
- 2012-05-02 US US14/114,835 patent/US10040855B2/en active Active
-
2013
- 2013-10-29 CR CR20130556A patent/CR20130556A/es unknown
- 2013-10-29 DO DO2013000252A patent/DOP2013000252A/es unknown
- 2013-10-30 CL CL2013003145A patent/CL2013003145A1/es unknown
- 2013-10-31 ZA ZA2013/08168A patent/ZA201308168B/en unknown
- 2013-10-31 MX MX2021008112A patent/MX2021008112A/es unknown
- 2013-10-31 MX MX2019009244A patent/MX2019009244A/es unknown
- 2013-10-31 IL IL229169A patent/IL229169B/en active IP Right Grant
- 2013-11-01 CO CO13259852A patent/CO6801648A2/es unknown
-
2017
- 2017-04-05 CL CL2017000829A patent/CL2017000829A1/es unknown
- 2017-05-10 JP JP2017094129A patent/JP6467457B2/ja active Active
- 2017-06-21 AU AU2017204192A patent/AU2017204192B2/en active Active
- 2017-09-28 HR HRP20171457TT patent/HRP20171457T1/hr unknown
- 2017-10-11 CY CY20171101057T patent/CY1119436T1/el unknown
- 2017-10-27 ZA ZA2017/07310A patent/ZA201707310B/en unknown
-
2018
- 2018-05-18 US US15/983,791 patent/US20180327497A1/en not_active Abandoned
- 2018-06-15 US US16/009,865 patent/US20180346578A1/en not_active Abandoned
- 2018-10-12 HK HK18113059.1A patent/HK1253911A1/zh unknown
- 2018-10-17 PH PH12018502221A patent/PH12018502221A1/en unknown
-
2019
- 2019-01-11 JP JP2019003265A patent/JP6751450B2/ja active Active
- 2019-07-17 PH PH12019501662A patent/PH12019501662A1/en unknown
- 2019-08-15 AU AU2019216679A patent/AU2019216679B2/en active Active
-
2020
- 2020-01-26 IL IL272237A patent/IL272237B/en unknown
- 2020-02-11 US US16/787,521 patent/US11560434B2/en active Active
- 2020-05-21 IL IL274846A patent/IL274846A/en unknown
- 2020-06-12 CL CL2020001579A patent/CL2020001579A1/es unknown
- 2020-08-14 JP JP2020136927A patent/JP7107997B2/ja active Active
-
2021
- 2021-04-23 US US17/239,512 patent/US20210340261A1/en active Pending
- 2021-08-31 AU AU2021225160A patent/AU2021225160B2/en active Active
-
2022
- 2022-02-23 IL IL290849A patent/IL290849A/en unknown
- 2022-02-23 IL IL290848A patent/IL290848A/en unknown
- 2022-06-10 EC ECSENADI202246340A patent/ECSP22046340A/es unknown
- 2022-07-14 JP JP2022112814A patent/JP2022132430A/ja active Pending
- 2022-10-13 US US18/046,450 patent/US20230312727A1/en active Pending
-
2023
- 2023-12-04 AU AU2023274233A patent/AU2023274233A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6801647A2 (es) | Formulación para anticuerpo anti-α4β7 | |
| CO6801648A2 (es) | Formulación para anticuerpo anti-α4β7 | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| BRDI7106210S (pt) | Configuração aplicada para lâmina para microscópio | |
| DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
| DK2858671T3 (da) | Antistofformulering | |
| DK3091029T3 (da) | Anti-IL13-antistofformuleringer | |
| CO7020871A2 (es) | Anticuerpos anti-il-36r | |
| DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
| BR112013022161A2 (pt) | dispositivo para injeção | |
| BR112013031813A2 (pt) | composição para aplicação tópica | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| CO6920293A2 (es) | Compuestos antibaterianos y método para su uso | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| BR112014008691A2 (pt) | anticorpos para cd1d | |
| BR112014000015A2 (pt) | formulação | |
| BR112013024413A2 (pt) | compostos e métodos para a preparação de diarilpropanos | |
| CO7010828A2 (es) | Preparación farmacéutica que comprende ßciclodextrina sustituida | |
| CO6841994A2 (es) | Anticuerpos | |
| CO6920303A2 (es) | Preparación plaguicida y procedimiento para su preparación | |
| BR112014010769A2 (pt) | métodos e composições para neuroproteção | |
| ES1075221Y (es) | Vallado cortavientos para parques termosolares | |
| ES1074173Y (es) | Pieza para solados | |
| DOP2011000313A (es) | Anticuerpos especificos para caderin-17 | |
| ES1076299Y (es) | Soporte para objetos |